Viravan Rx-to-OTC switch?
This article was originally published in The Tan Sheet
Executive Summary
PediaMed Pharmaceuticals is assessing OTC potential of its "switchable" products including its Viravan pediatric antihistamine/decongestant line, according to incoming President Cameron Durrant, MD. Durrant, whose appointment was announced Aug. 7, was VP-global business planning at Pharmacia and previously held senior positions in sales and marketing with GlaxoWellcome and Merck in the U.K. PediaMed grew from nine employees and revenue under $1 mil. in 2001 to around 75 employees and revenue in the "tens of millions" in FY 2003, according to Durrant. The new president says the firm's strengths lie in its healthy pipeline and drug delivery technology. Pediamed's only current OTC offering is Klout lice removal treatment...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.